Fever following immunization

Expert Review of Vaccines

Volumn 4, Issue 3, 2005, Pages 419-427

  Tapiainen, Terhi ^a   Heininger, Ulrich ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Adverse event following immunization; Case definition; Fever; Immunization

Indexed keywords

ANTIPYRETIC AGENT; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PARACETAMOL; PERTUSSIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VACCINE;

CLINICAL PRACTICE; CLINICAL TRIAL; CORE TEMPERATURE; FEBRILE CONVULSION; FEVER; FOLLOW UP; HUMAN; IMMUNIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; VIRUS INFECTION;

FEVER; HUMANS; TIME FACTORS; VACCINATION;

EID: 22144450694     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.3.419     Document Type: Review

References (73)

1. Mackowiak PA. Concepts of fever. Arch. Intern. Med. 158(17), 1870-1881 (1998). Useful review on the history of temperature measurements and current knowledge on thermoregulation and febrile response.
2. Blatteis CM, Sehic E, Li S. Pyrogen sensing and signaling: old views and new concepts. Clin. Infect. Dis. 31(Suppl.5), S168-S177 (2000).
3. Craig JV, Lancaster GA, Williamson PR, Smyth RL. Temperature measured at the axilla compared with rectum in children and young people: systematic review. British Medical Journal 320, 1174-1178 (2000).
4. Crocetti M, Moghbeli N, Serwint J. Fever phobia revisited: have parental misconceptions about fever changed in 20 years? Pediatrics 107(6), 1241-1246 (2001).
5. Ipp M, Jaffe D. Physicians' attitudes toward the diagnosis and management of fever in children 3 months to 2 years of age. Clin. Pediatr. (Philo.) 32(2), 66-70 (1993).
6. Marcy M, Rogers R, Mackowiak PA. High fevers as a cause of central nervous system sequelae. Pediatr. Infect. Dis. J. 22(3), 294-295 (2003).
7. Doran TF, De Angelis C, Baumgardner RA, Mellits ED. Acetaminophen: more harm than good for children with chickenpox? J. Pediatr. 114, 1045-1048 (1988).
8. Graham MH, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J. Infect. Dis. 162, 1277-1282 (1990).
9. Greisman LA, Mackowiak PA. Fever: beneficial and detrimental effects of antipyretics. Curr. Opin. Infect. Dis. 15(3), 241-245 (2002).
10. Meremikwu M, Oyo-Ita A. Paracetamol for treating fever in children. Cochrane Database Syst. Rev. 2 (2002).
11. Kramer MS, Naimark LE, Roberts-Brauer R, McDougall A, Leduc DG. Risks and benefits of paracetamol antipyresis in young children with fever of presumed viral origin. Lancet 337, 591-594 (1991).
12. Zhou W, Pool V, Iskander JK et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-US, 1991-2001. Morbid. Mortal. Wkly Rep. Surveill. Summ. 52(1), 1-24 (2003).
13. Uhari M, Möttönen M. An open randomized controlled trial of infection prevention in child day-care centers. Pediatr. Infect. Dis. J. 18(8), 672-677 (1999).
14. De Serres G, Duval B, Boulianne N et al. Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. Am. J. Public Health 91(2), 313-315 (2001). Presents the fever rate attributable to immunization using control data on the fever rate 1 month before immunization (i.e., the background rate).
15. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1, 939-42 (1986). One of the few vaccine studies to use a placebo group to assess the fever rate attributable to immunization with measles-mumps-rubella (MMR).
16. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am. J. Epidemiol. 136(2), 121-135 (1992).
17. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 106(5), E62 (2000).
18. Schmitt-Grohe S, Stehr K, Cherry JD et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Dev. Biol. Stand. 89, 113-118 (1997).
19. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334(6), 349-355 (1996).
20. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334(6), 341-348 (1996).
21. Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96, 557-566 (1995). Study containing detailed information regarding the occurrence of febrile responses after immunization with acellular pertussis vaccines.
22. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68(5), 650-660 (1981).
23. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 73(1), 31-36 (1984)
24. Deloria MA, Blackwelder WC, Decker MD et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 96, 592-594 (1995).
25. Christy C, Pichichero ME, Reed GF et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 96, 584-587 (1995).
26. Englund JA, Anderson EL, Reed GF et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96, 580-584 (1995).
27. Baraff LJ, Manclark CR, Cherry JD, Christenson P, Marcy SM. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr. Infect. Dis. J. 8(8), 502-507 (1989).
28. Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics 91(6), 1158-1165 (1993).
29. Lewis K, Cherry JD, Sachs MH et al. The effect of prophylactic acetaminophen administration on reactions to DTP vaccination. Am. J. Dis. Child. 142(1), 62-65 (1988).
30. Ipp MM, Gold R, Greenberg S et al. Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr. Infect. Dis. J. 6(8), 721-725 (1987).
31. Tozzi AE, Anemona A, Stefanelli P et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 107(2), E25 (2001).
32. Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev. 2 (2000). Systematic review which includes a meta-analysis of vaccine safety data of acellular versus pertussis vaccines compared with whole-cell pertussis vaccine.
33. Mallet E, Belohradsky BH, Lagos R et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 22(11-12), 1343-1357 (2004).
34. Zepp F, Knuf M, Heininger U et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22(17-18), 2226-2233 (2004). Review summarizing safety data (including febrile responses) observed after immunization with a hexavalent pediatric combination vaccine.
35. Mallet E, Fabre P, Pines E et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J. 19(12), 1119-1127 (2000).
36. McDonald P, Friedman EH, Banks A, Anderson R, Carman V. Pneumococcal vaccine campaign based in general practice. British Medical Journal 314, 1094-1098 (1997).
37. Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281(3), 243-248. (1999).
38. Shinefield HR, Black S, Ray P et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 18(9), 757-763 (1999).
39. Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101(4 Pt 1), 604-611 (1998).
40. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6), 403-409 (2001).
41. Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 333(14), 889-893 (1995). Placebo-controlled study of adverse events after influenza vaccination demonstrating that the rate of fever does not differ in placebo and vaccine recipients.
42. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 264(9), 1139-1141 (1990).
43. Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double-blind placebo-controlled trial. British Medical Journal 307, 988-990 (1993).
44. Neuzil KM, DuPont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr. Infect. Dis. J. 20(8), 733-740 (2001).
45. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 18(11-12), 1074-1080 (2000).
46. Miller C, Miller E, Rowe K, Bowie C, Judd M, Walker D. Surveillance of symptoms following MMR vaccine in children. Practitioner 233, 69-73 (1989).
47. Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 68(1), 18-22 (1981).
48. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr. Infect. Dis. J. 18(1), 42-48 (1999).
49. Norrby E, Lagercrantz R, Gard S. Vaccination against measles: a study of clinical reactions and serological responses of young children. A report to the medical council by the measles vaccines committee. British Medical Journal 5438, 817-823 (1965).
50. Cherry JD. Measles virus. Textbook of Pediatric Infectious Diseases (Volume 2, 4th Edition). Feigin RD, Cherry JD (Eds). WB Saunders Company, PA, USA, 2061 (1998).
51. Kobune F, Funatu M, Takahashi H et al. Characterization of measles viruses isolated after measles vaccination. Vaccine 13(4), 370-372 (1995).
52. Morfin F, Beguin A, Lina B, Thouvenot D. Detection of measles vaccine in the throat of a vaccinated child. Vaccine 20(11-12), 1541-1543 (2002).
53. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 78, 748-756 (1986).
54. Black S, Shinefield H, Ray P et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr. Infect. Dis. J. 18(12), 1041-1046 (1999).
55. Nolan T, McIntyre P, Roberten D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 21(3-4), 281-289 (2002).
56. Shinefield HR, Black SB, Staehle BO et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr. Infect. Dis. J. 21(6), 555-561 (2002).
57. Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. 39(7), 920-927 (2004).
58. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
59. Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110(4), 662-672 (2002).
60. Walker AM, Jick H, Perera DR, Knauss TA, Thompson RS. Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 81(3), 345-349 (1988).
61. Barlow WE, Davis RL, Glasser JW et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N. Engl. J. Med, 345(9), 656-661 (2001). Presents data on the number of febrile seizures attributable to immunization with diphtheria tetanus pertussis and MMR vaccines.
62. Farrington P, Pugh S, Colville A et al. A new method for active surveillance of adverse events from diphtheria-tetanus-pertussis and measles-mumps-rubella vaccines. Lancet 345, 567-569 (1995).
63. Vestergaard M, Hviid A, Madsen KM et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and longterm prognosis. JAMA 292(3), 351-357 (2004). Recently published nationwide study regarding febrile seizures and MMR vaccination.
64. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112(5), E348 (2003).
65. Berg AT, Shinnar S, Shapiro ED, Salomon ME, Crain EF, Hauser WA. Risk factors for a first febrile seizure: a matched case-control study. Epilepsia 36(4), 334-341 (1995).
66. van Stuijvenberg M, Derksen-Lubsen G, Steyerberg EW, Habbema JD, Moll HA. Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences. Pediatrics 102(5), E51 (1998).
67. Schnaiderman D, Lahat E, Sheefer T, Aladjem M. Antipyretic effectiveness of acetaminophen in febrile seizures: ongoing prophylaxis versus sporadic usage. Eur. J. Pediatr. 152(9), 747-749 (1993).
68. Chen RT, Pool V, Takahashi H, Weniger BG, Patel B. Combination vaccines: postlicensure safety evaluation. Clin. Infect. Dis. 33(Suppl.4), S327-333 (2001).
69. Bonhoeffer J, Zumbrunn B, Heininger U. Reporting of vaccine safety data in publications: systematic review. Pharmacoepidemiol. Drug Saf. 14(2), 101-106 (2004). Systematic review demonstrating the heterogeneity of case definitions used for fever in vaccine safety data.
70. Bonhoeffer J, Kohl K, Chen R et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21(3-4), 298-302 (2002).
71. Kohl KS, Bonhoeffer J, Chen R et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol. Drug Saf. 12(4), 335-340 (2003).
72. Marcy MS, Kohl KS, Dagan R et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 22(5-6), 551-556 (2004). Presents the now available standardized case definition for fever.
73. Brook I. Unexplained fever in young children: how to manage severe bacterial infection. British Medical Journal 327, 1094-1097 (2003).